Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

By sjmartinez • March 25, 2025

Bender Ignacio RA, Chew KW, Moser C, Currier JS, Eron JJ, Javan AC, Giganti MJ, Ritz J, Gibbs M, Kouekam HT, Esser MT, Daar ES, Choudhary M, Deo R, Fletcher CV, Li JZ, Hughes MD, Smith D, Wohl DA; ACTIV-2/A5401 Study Team. Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies. iScience. 2025 Feb 4;28(3):111938. doi: 10.1016/j.isci.2025.111938. PMID: 40124489; PMCID: PMC11927737.

Tags: Harbor UCLA, Health sciences, Immunology, Infectious Diseases, Medical specialty, medicine, Publications

Periods of susceptibility for associations between phthalate exposure and preterm birth: Results from a pooled analysis of 16 US cohorts

Friedman A, Welch BM, Keil AP, Bloom MS, Braun JM, Buckley JP, Dabelea D, Factor-Litvak P, Meeker JD, Michels KB, Padmanabhan V, Starling AP, Weinberg[...]

Measuring parameters of aerobic function during exercise: One protocol to rule them all?

Poole DC, Rossiter HB. Measuring parameters of aerobic function during exercise: One protocol to rule them all? Exp Physiol. 2025 Mar 22. doi: 10.1113/EP092732. Epub[...]

SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)

Sábato S, Benet S, Rogers AJ, Murray TA, Skeans M, Mothe B, Paredes R, Mourad A, Kiweewa F, Kamel D, Jain MK, Lutaakome J, Nalubega[...]